Method Article

Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization

3.8K views

⸱

DOI:

10.3791/61545

⸱

December 3rd, 2020

 ,  ,  ,  ,  , 
1The Children's Hospital of Philadelphia, 2Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania

* These authors contributed equally

In This Article

Summary

Presented here is a protocol for appending peptide CD47 (pepCD47) to metal stents using polybisphosphonate chemistry. Functionalization of metal stents using pepCD47 prevents the attachment and activation of inflammatory cells thus improving their biocompatibility.

Abstract

The key complications associated with bare metal stents and drug eluting stents are in-stent restenosis and late stent thrombosis, respectively. Thus, improving the biocompatibility of metal stents remains a significant challenge. The goal of this protocol is to describe a robust technique of metal surface modification by biologically active peptides to increase biocompatibility of blood contacting medical implants, including endovascular stents. CD47 is an immunological species-specific marker of self and has anti-inflammatory properties. Studies have shown that a 22 amino acid peptide corresponding to the Ig domain of CD47 in the extracellular region (pepCD47), has anti-inflammatory properties like the full-length protein. In vivo studies in rats, and ex vivo studies in rabbit and human blood experimental systems from our lab have demonstrated that pepCD47 immobilization on metals improves their biocompatibility by preventing inflammatory cell attachment and activation. This paper describes the step-by step protocol for the functionalization of metal surfaces and peptide attachment. The metal surfaces are modified using polyallylamine bisphosphate with latent thiol groups (PABT) followed by deprotection of thiols and amplification of thiol-reactive sites via reaction with polyethyleneimine installed with pyridyldithio groups (PEI-PDT). Finally, pepCD47, incorporating terminal cysteine residues connected to the core peptide sequence through a dual 8-amino-3,6-dioxa-octanoyl spacer, are attached to the metal surface via disulfide bonds. This methodology of peptide attachment to metal surface is efficient and relatively inexpensive and thus can be applied to improve biocompatibility of several metallic biomaterials.

Introduction

Percutaneous coronary intervention is the first line of therapy to treat coronary artery diseases (CAD) and primarily involves stenting the diseased arteries. However, in-stent restenosis (ISR) and stent thrombosis are common complications associated with stent deployment1. Blood interaction at the blood-stent interface is characterized by an almost immediate adsorption of plasma proteins on the metal surface, followed by platelet and inflammatory cell attachment and activation2. The release of the inflammatory cytokines and chemokines from activated inflammatory cells leads to the phenotypic modification of the vascular smooth muscle cells (VSMCs) in the tunica media and triggers their centripetal migration to the intimal compartment. Proliferation of activated VSMC in the intima results in intimal layer thickening, lumen narrowing and in-stent restenosis3. Drug eluting stents (DES) were developed to prevent VSMC proliferation; however, these drugs have an off-target cytotoxic effect on the endothelial cells4,5. Therefore, late stent thrombosis is a common complication associated with DES6,7. Stents made of biodegradable polymers, such as poly-L-lactide have shown much promise in the animal experiments and initial clinical trials, but were eventually recalled when the “real-life” clinical use demonstrated their inferiority to the 3rd generation DES8. Therefore, there is a need to improve the biocompatibility of bare metal stents for better patient outcomes.

CD47 is a ubiquitously expressed transmembrane protein that inhibits the innate immune response when bound to its cognate receptor Signal Regulatory Protein alpha (SIRPα)9. The SIRPα receptor has an immune cell tyrosine inhibitory motif (ITIM) domain and the signaling events upon SIRPα - CD47 interaction ultimately result in the downregulation of inflammatory cell activation10,11,12,13. Research in our lab has shown that recombinant CD47 or its peptide derivative, corresponding to the 22 amino acid Ig domain of the extracellular region of CD47 (pepCD47), can reduce the host immune response to a range of clinically relevant biomaterials14,15,16. Recently, we have demonstrated that pepCD47 can be immobilized to stainless steel stent surfaces and significantly reduce the pathophysiological response associated with restenosis. Of note, the pepCD47 modified surfaces are amenable to relevant usage conditions such as long term storage and ethylene oxide sterilization17. To that end, pepCD47 may be a useful therapeutic target to address the clinical limitations of endovascular stents.

The strategy for the covalent attachment of pepCD47 to a metal surface involves a series of novel chemical modifications of the metal surface. The metal surfaces are first coated with polyallylamine bisphosphonate with latent thiol groups (PABT) followed by the deprotection of the thiols and attachment of polyethyleneimine (PEI) with installed pyridyldithio groups (PDT). PDT groups of PEI unconsumed in the reaction with deprotected PABT thiols are then reacted with pepCD47 incorporating thiols in the terminal cysteine residues, resulting in binding pepCD47 to the metal surface via a disulfide bond14,17,18. We used a fluorophore conjugated pepCD47 (TAMRA-pepCD47) to determine the input concentration of peptide that results in the maximum surface immobilization of the peptide. Finally, we evaluated the acute and chronic anti-inflammatory capacity of the pepCD47 coated metal surfaces, ex vivo, using the Chandler loop apparatus, and monocyte attachment/macrophage expansion assay, respectively.

This paper provides a systematic protocol for the attachment of thiolated peptides to the metal surface; determining the maximum immobilization density of the peptide; and assessing the anti-inflammatory properties of pepCD47 coated metal surfaces exposed to whole blood and isolated monocytes.

Access restricted. Please log in or start a trial to view this content.

Protocol

All human samples for this experiment were obtained in accordance with the IRB of the Children’s Hospital of Philadelphia. All animal experiments were performed upon approval from IACUC of the Children’s Hospital of Philadelphia.

1. Coating bare metal surfaces with PEI-PDT

  1. Wash the stainless steel foil coupons (1 cm x 1 cm or 0.65 cm x 1 cm) or stainless steel mesh disks with 2-isopropanol  in a shaker (60 °C, speed of 200 rpm) for 5 min. Perform this step 2x. Then wash 2x with chloroform (60 °C, speed of 200 rpm) for 10 min each.
  2. Place the cleansed stainless-steel samples in an oven at 220 °C for 30 min.
  3. Prepare 5 mL of 0.5% of PABT solution by dissolving 25 mg of polyallylamine bisphosphonate with latent thiol groups (PABT) and 5 mg of potassium bicarbonate (KHCO3) in 5 mL of DDW and incubate at 72 °C in a shaker at 200 rpm for 30 min.
    NOTE: For PABT synthesis refer to previously published literature18.
  4. Immerse the baked foils or mesh disks in 0.5% aqueous solution of PABT and incubate in a shaker (72 °C, speed of 200 rpm) for 1 h.
  5. Wash the PABT-modified samples with deionized distilled water (DDW) for 5x, transfer the specimens in a new vial and wash again with DDW for 5x.
  6. Prepare a total of 5 mL of TCEP solution (12 mg/mL) by dissolving 60 mg of Tris (2-carboxyethyl) phosphine hydrochloride (TCEP) in 5 mL of 0.1 M acetic buffer (0.57 mL of glacial acetic acid, 820 mg of sodium acetate in 100 mL of DDW).
  7. Treat the PABT-modified samples with TCEP for 15 min at room temperature (RT) on a shaker.  
    NOTE: TCEP is used to deprotect the thiol groups.
  8. Degas DDW in a round bottom flask by using a vacuum generating device, such as a lyophilizer and wash the TCEP treated foils or mesh disks with degassed DDW for 5x. Transfer the samples in a new vial, and additionally wash 5x with degassed DDW.
    NOTE: It is paramount to work fast to prevent oxidation of thiols on the metal surface by atmospheric oxygen.
  9. Prepare 5 mL of 1% PEI-PDT solution by diluting 212.5 µL of stock PEI-PDT and 125 µL of 0.4 M sodium acetate in degassed DDW. Carry out step 1.9 simultaneously with step 1.8 to minimize exposure of the samples to atmospheric air.
    NOTE: The synthesis of PEI-PDT is described in previously published literature18.
  10. Incubate the washed stainless-steel specimens with 1% PEI-PDT. Replace air with argon gas, seal the vials air-tight and mix on a shaker at RT for 1 h. Either proceed immediately with the peptide conjugation or store at 4 °C up to 1 week.

2. Attachment and qualitative/quantitative assessment of fluorophore conjugated pepCD47 retention on metal surface using fluorescence microscopy and fluorimetry

  1. Wash foil coupons or mesh disks prepared as described in the section 1, steps 1.1-1.10 above with DDW 5x. Transfer the samples to a new vial and wash with DDW for additional 5x. Finally wash 2x with degassed ethanol and 2x with degassed dimethyl formamide (DMF).
  2. Prepare tetramethylrhodamine (TAMRA)-conjugated pepCD47 stock solution by dissolving TAMRA-conjugated pepCD47 powder in degassed dimethylformamide (DMF) to a final concentration of 1 mg/mL. Aliquot the stock solution in 1 mL allotments. Store in well-sealed tubes under argon atmosphere at -20 °C.
  3. Dilute 1 mg/mL of the stock solution of TAMRA-conjugated pepCD47 using degassed DMF to prepare the following concentrations of fluorophore conjugated pepCD47 - 10, 30, 100, and 200 µg/mL.
    NOTE: If TAMRA-conjugated pepCD47 appears to be precipitated, reduce the stock TAMRA-conjugated pepCD47 solution using TCEP beads in ratio 1:1, at RT for 20 min. Note that before adding the TAMRA-conjugated pepCD47 to the TCEP beads, spin the TCEP beads solution, remove the supernatant and then proceed with addition of the TAMRA-conjugated pepCD47.
  4. Incubate the PEI-PDT modified foil coupons with 10, 30, 100 or 200 µg/mL of TAMRA-conjugated pepCD47 in triplicates for each condition on a shaker at RT under argon atmosphere for 1 hour. Incubate PEI-PDT modified mesh disks, as well as mesh disk not modified beyond step 1.2 (bare metal controls) with 100 µg/mL of TAMRA-conjugated pepCD47 in triplicates at RT under argon atmosphere on a shaker for 1 h.
    NOTE: From this step onwards, the vials are wrapped in aluminum foil to protect the contents from light.
  5. Wash the fluorophore conjugated pepCD47-coated surfaces to remove the non-covalently attached peptide in the following order: DMF (3x), DMF/DDW at 1:1, DDW (3x), 0.3% SDS in 20 mM Tris pH 7.4   (3x, 5 min each at 70 °C on a shaker), DDW (3x), change vials, and a final DDW wash.
  6. Place control and covalently conjugated mesh disks on a microscope glass, add 50 µL of PBS and place a coverslip. Image mesh disks using an inverted fluorescence microscope equipped with a rhodamine filter set. Take representative images at 100x magnification.
  7. Prepare 15 mL of 12 mg/mL TCEP solution by dissolving 180 mg of TCEP in 1:1 v/v mixture of methanol and 0.1 M acetic buffer.
  8. Incubate each washed foil with 1 mL of TCEP solution on a shaker at RT for 15 min.
  9. Prepare the following standards by serially diluting the TAMRA-conjugated pepCD47 stock (1 mg/mL) – 100 µg/mL, 10 µg/mL, 1 µg/mL, 0.1 µg/mL, and 0.01 µg/mL. Use the TCEP solution as the diluent.
  10. Analyze the TAMRA-conjugated pepCD47 released from the metal surface against the calibration curve generated using the standards by fluorimetry at 544/590 nm excitation and emission wavelengths.

3. Attaching human pepCD47 to PEI-PDT modified surfaces

  1. Wash PEI-PDT coated samples formulated as described in the section 1, steps 1.1-1.10 above, with degassed DDW 5x, change the vial and wash with degassed DDW 5x.
  2. Prepare human pepCD47 stock solution (1 mg/mL) by dissolving human pepCD47 powder in degassed 50% acetic acid to achieve a concentration 1 mg/mL.
  3. Prepare working concentration of human pepCD47 (100 µg/mL) by dissolving 500 µL of the stock of human pepCD47 in 4,500 µL of degassed 1x phosphate buffered saline (PBS).
  4. Incubate the washed PEI-PDT coated samples with 100 µg/mL of pepCD47 at RT with shaking for 1 h.
  5. Wash the human pepCD47-coated samples to remove excess peptide in the following order PBS (3x), DDW (3x), 0.2% Tween-20 (3x, 5 min each), DDW (3x), change vials and final DDW wash.
    NOTE: Human pepCD47 coated surfaces can be stored dry at 4 °C for up to 6 months.

4. Coating the PEI-PDT modified surfaces with scrambled sequence (Scr)

  1. Dissolve the scrambled sequence powder in degassed 0.1% acetic acid to prepare a stock solution of 1 mg/mL.
  2. Prepare a solution of 100 µg/mL of scrambled peptide by dissolving 500 µL of the in 4,500 µL of degassed 0.1% acetic acid.
  3. Coat the washed PEI-PDT specimens with 100 µg/mL of scrambled peptide at RT with shaking for 1 h.
  4. To remove unattached scrambled peptide, wash the surfaces in the following order 0.01% acetic acid (3x), DDW (3x), 0.2% Tween-20 (3x, 5 min), DDW (3x), change vials and one DDW wash.

5. Chandler loop for analyzing cellular attachment to metal surfaces

  1. Coat the metal foils (0.65 cm x 1cm) with either human pepCD47 or scrambled peptide as per the description on section 1 followed by 3 or 4.
  2. Cut ¼” PVC tubes into three 38 cm long pieces.
  3. Insert up to 8 unmodified, scrambled peptide or pepCD47 modified metal foils in three different tubes.
  4. Collect 30 mL of blood from healthy human donors free of any anti-platelet medications as per institutional IRB protocol. Preload syringe with 1 mL of 4% sodium citrate to prevent coagulation of collected blood.
  5. Put 10 mL of blood into each tube using a 10 mL syringe and connect the ends with metal adapters. Place the blood-filled tubes on the wheels of the Chandler loop apparatus.
  6. Pass the blood along the metal foils by wheel rotation at 37 °C at the speed calculated to produce the shear of 25 dyns/cm2 for 4 h.
  7. Drain the blood from the tubes and dispose of the blood according to the IRB requirements.
  8. Cut the tubes using the scalpel to retrieve the foils from each tube.
  9. Prepare 2% glutaraldehyde solution by diluting the 10 ml of 4% glutaraldehyde solution using 10 mL of sodium cacodylate buffer with 0.1 M sodium chloride.
  10. Incubate the foils in 2% glutaraldehyde solution for 15 min and store at 4 °C overnight. Before analyzing, wash the metal foils 3x with PBS.

6. Analyzing cellular attachment to metal surfaces using CFDA dye

  1. Warm 8 mL of PBS in 15 mL tube in a water bath set to 37 °C.
  2. Prepare the CFDA (carboxy-fluorescein diacetate, succinimidyl ester) dye solution as follows - add 90 µL of DMSO to one CFDA dye vial to achieve a stock concentration of 10 mM. Next, prepare the working concentration of 93.75 µM by adding 75 µL of the stock CFDA to 8 mL of warm PBS. Mix by inverting the tubes a few times and cover the tube with aluminium foil.
    NOTE: It is advisable to freshly prepare the CFDA dye before every use.
  3. Incubate each foil with 1 mL of CFDA dye in a 24 well plate. Cover the plate with aluminum foil and incubate the plate at 37 °C for 15 min.
  4. Wash the metal foils 3x with PBS to remove excess dye. Image using the inverted fluorescence microscope.

7. Monocyte attachment and macrophage expansion on the pepCD47-modified and bare metal surfaces

  1. Collect 10 mL of peripheral blood via the vena cava access during the sacrifice of a 400-450 g male Sprague-Dawley rat. Mix immediately with 1,000 IU of sodium heparin to prevent coagulation.
  2. Pipette 10 mL of density gradient medium into a 50 mL conical tube. Mix the blood with 5 mL of PBS, and carefully layer diluted blood over the density gradient medium using a Pasteur pipette. Centrifuge in a swinging bucket rotor at 800 x g and 18-25 °C for 20 min with minimal settings of acceleration and deceleration.
  3. Using a Pasteur pipette, collect an opaque layer of buffy coat on the interface between plasma and Ficoll. Dilute buffy coat 1:3 with PBS and centrifuge at 550 x g and 4 °C for 10 min to buffy coat cells.
  4. Re-suspend buffy coat cells in 3 mL of ACK lysis buffer to lyse contaminating erythrocytes. Incubate on ice for 4 min. Add 12 mL of cell separation buffer (CSB; 0.5% BSA, 0.5% FBS, 2 mM EDTA/PBS).
  5. Centrifuge at 550 x g and 4 °C for 10 min. Re-suspend the pellet in 10 mL of CSB.
  6. Centrifuge at 200 x g and 4 °C for 10 min to eliminate platelets. Repeat twice.
  7. Re-suspend the pellet in 500 µL of CSB. Add 10 µg of each of the following mouse anti-rat antibodies: CD8a (clone OX-8), anti-CD5 (clone OX-19), anti-CD45RA (clone OX-33), and anti-CD6 (clone OX-52).
  8. Incubate at 4 °C on a vertical tube rotator for 1 h. Add 9.5 mL of CSB. Centrifuge at 300 x g and 4 °C for 10 min. Discard supernatant, re-suspend the pellet in 10 mL of CSB and repeat centrifugation.
  9. Re-suspend the pellet in 500 µL of CSB. Add 150 µL of goat anti-mouse IgG microbeads. Incubate at 4 °C on a vertical tube rotator for 20 min. Add 9.5 mL of CSB. Centrifuge at 300 x g and 4 °C for 10 min.
  10. Discard the supernatant. Re-suspend the pellet in 1 mL of CSB.
  11. Place a LS column in a magnetic separator.  Prime the LS column with 3 mL of CSB. Discard the column throughput. Add 1 mL of re-suspended cell pellet from the step 7.10. Start collecting the throughput. After flow stops, add 5 mL of CSB and keep collecting the column throughput until the flow stops.
  12. Centrifuge the column throughput (6 mL) containing negatively selected monocytes at 300 x g and 4 °C for 10 min. Re-suspend the resulting small pellet in 2 mL of RPMI-1640 medium supplemented with 10% FCS, 1% pen/strep and 100 ng/mL rat macrophage colony stimulating factor (M-CSF).
  13. Count the monocytes using hemocytometer. Adjust monocyte concentration to 5 x 105 cells/mL.
  14. Add 1 mL volumes of monocyte suspension to the individual wells of a 12 well plate with the bare stainless steel foil samples (N=3) or stainless steel samples modified with rat pepCD47 (N=3) as per 1.1-1.10 and 3.1-3.6.
  15. Change the medium on days 3 and 5 post-seeding. On day 6 post-seeding wash the cells with PBS and fix with 4% paraformaldehyde at room temperature for 15 min. Wash twice with PBS for 5 min.
  16. Remove the stainless-steel foils and place them individually into a new 12 well plate. Do not flip the foils.
  17. Incubate in 0.5% Tween-20/PBS for 15 min to permeabilize the cells. Wash twice with PBS for 5 min.
  18. Block in 10% goat serum/PBS for 20 min. Aspirate the serum. Do not wash. Add mouse anti-rat CD68 antibody (diluted 1:100 in 1%BSA/PBS). Incubate at room temperature for 1 h. Wash 3x in PBS for 5 min each.
  19. Add goat anti-mouse IgG Alexa Fluor 546 (diluted 1:200 in 1% BSA/PBS). Incubate in dark at room temperature for 45 min. Wash in PBS for 5 min. Counterstain with 1 µg/mL Hoechst 33342 dye in dark at room temperature for 10 min. Wash 3x in PBS for 5 min each.
  20. Flip the foils and image using a fluorescent microscope with the inverted optics. Capture images at 200x magnification with blue and red filter settings.
  21. Count the attached monocytes in the individual images and calculated the group averages and standard deviations.

Access restricted. Please log in or start a trial to view this content.

Results

The metal surfaces are rendered thiol-reactive for peptide attachment via a series of chemical modifications, as illustrated in Figure 1. PABT incubation followed by PEI-PDT treatment makes the metal surface amenable for peptide attachment. Peptide CD47 (pepCD47) containing cysteine residue at C-terminus joined to the core pepCD47 sequence through a flexible dual AEEAc bridge is covalently attached to the thiol-reactive surfaces via disulfide bonds. Using this protocol, we have demonstrated ...

Access restricted. Please log in or start a trial to view this content.

Discussion

We demonstrate and describe a relatively novel chemical strategy to append therapeutic peptide moieties to a stainless-steel surface with the overarching goal of reducing the surface’s reactivity with inflammatory cells found in blood. The bisphosphonate chemistry described herein involves co-ordinate bond formation between the metal oxides and bisphosphonate groups of PABT. The thickness of polybisphosphonate monolayer formed on the metal surface does not exceed 5 nm18, and, therefore, is i...

Access restricted. Please log in or start a trial to view this content.

Disclosures

The authors have nothing to disclose.

Acknowledgements

Protocol development and studies presented in this paper were supported by NIH (NBIB) R01 funding (# EB023921) to IF and SJS, and NIH (NHLBI) R01 funding (# HL137762) to IF and RJL.

Access restricted. Please log in or start a trial to view this content.

Materials

List of materials used in this article
NameCompanyCatalog NumberComments
1 M Tris-HCLInvitrogen15567-027pH - 7.5
4% GlutaraldehydeElectron Microscopy Sciences16539-07
4% Sodium CitrateSigmaS5770
ACK lysing bufferQuality Biologicals118-156-721
anti-CD45RA Ab (mouse anti-rat; clone OX-19)Biolegend202301
anti-CD5 Ab (mouse anti-rat; clone OX-19)Biolegend203501
anti-CD6 Ab (mouse anti-rat; clone OX-52)BD Biosciences550979
anti-CD68 Ab (mouse anti-rat; clone ED-1)BioRadMCA341
anti-CD8a Ab (mouse anti-rat; clone OX-8)Biolegend201701
Chloroform Certified ACSFisher ChemicalC298-500
Dimethyl Formammide (DMF)Alfa Aesar39117
Embra stainless steel gridElectron Microscopy SciencesE200-SSstainless steel mesh mesh disks
Ficoll HypaqueGE Healthcare17-1440-02
Glacial acetic acidACROS organic148930025
goat anti-mouse IgG Alexa FluorThermoFisherA11030
Heparin sodiumSagent Pharmaceuticals402-01
Human pepCD47Bachem4099101
IsopropanolFisher ChemicalA426P-4
Metal adaptersLeur Fitting6515IND1 way adapter 316 ss 1/4"-5/16" hoes end
MethanolRICCA chemical company4829-32
MicroscopeNikon EclipseTE300
Phosphate buffered saline (PBS)Gibco14190-136
Pottasium Bicarbonate (KHCO3)Fisher ChemicalP184-500
PVC tubesTerumo-CVS600501/4" X 1/16 8'
sodium cacodylate buffer with 0.1M sodium chlorideElectron Microscopy Sciences11653
Sodium Dodecyl Sulfate (SDS)Bio-Rad laboratories161-0302
Sodum actetate (C2H3NaO2)Alfa AesarA13184
Src peptideBachem4092599
Stainless steel (AISI 304) cylinder-shaped samples with a lumenMicrogroup, Medway, MA200973281 cm X 6 mm OD
Stainless steel foils (AISI 316L)Goodfellow, Coraopolis, PA100 mm X 100 mm X 0.05 mm
Tetramethylrhodamine-conjugated pepCD47 (TAMRA-pepCD47)Bachem4100277
TMB (3,3’ ,5,5’ -tetramethylbenzidine) substrate and tris (2-carboxyethyl) phosphine hydrochloride (TCEP)Thermo ScientificPG82089
Tween-20Bio-Rad laboratories170-6531
Vybrant CFDA SE Cell Tracer KitInvitrogenV12883

References

  1. Buccheri, D., Piraino, D., Andolina, G., Cortese, B. Understanding and managing in-stent restenosis: a review of clinical data, from pathogenesis to treatment. Journal Thoracic Disease. 8 (10), 1150-1162 (2016).
  2. van Oeveren, W. Obstacles in haemocompatibility testing. Scientifica. 2013, Cairo. 392584(2013).
  3. Mitra, A. K., Agrawal, D. K. In stent restenosis: bane of the stent era. Journal of Clinical Pathology. 59 (3), 232-239 (2006).
  4. Iqbal, J., Gunn, J., Serruys, P. W. Coronary stents: historical development, current status and future directions. British Medical Bulletin. 106, 193-211 (2013).
  5. Hoffmann, R., et al. Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation. 94 (6), 1247-1254 (1996).
  6. Stefanini, G. G., Windecker, S. Stent thrombosis: no longer an issue with newer-generation drug-eluting stents. Circulation: Cardiovascular Interventions. 5 (3), 332-335 (2012).
  7. Palmerini, T., et al. Clinical outcomes with bioabsorbable polymer- versus durable polymer-based drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Journal of the American College of Cardiology. 63 (4), 299-307 (2014).
  8. Omar, W. A., Kumbhani, D. J. The Current Literature on Bioabsorbable Stents: a Review. Current Atherosclerosis Reports. 21 (12), 54(2019).
  9. Slee, J. B., Christian, A. J., Levy, R. J., Stachelek, S. J. Addressing the Inflammatory Response to Clinically Relevant Polymers by Manipulating the Host Response Using ITIM Domain-Containing Receptors. Polymers (Basel). 6 (10), 2526-2551 (2014).
  10. Oldenborg, P. A., et al. Role of CD47 as a marker of self on red blood cells. Science. 288 (5473), 2051-2054 (2000).
  11. vanden Berg, T. K., vander Schoot, C. E. Innate immune 'self' recognition: a role for CD47-SIRPalpha interactions in hematopoietic stem cell transplantation. Trends in Immunology. 29 (5), 203-206 (2008).
  12. Tengood, J. E., Levy, R. J., Stachelek, S. J. The use of CD47-modified biomaterials to mitigate the immune response. Experimental Biology Medicine (Maywood). 241 (10), 1033-1041 (2016).
  13. Tsai, R. K., Rodriguez, P. L., Discher, D. E. Self inhibition of phagocytosis: the affinity of 'marker of self' CD47 for SIRPalpha dictates potency of inhibition but only at low expression levels. Blood Cells, Molecules and Diseases. 45 (1), 67-74 (2010).
  14. Slee, J. B., et al. Enhanced biocompatibility of CD47-functionalized vascular stents. Biomaterials. 87, 82-92 (2016).
  15. Finley, M. J., et al. Diminished adhesion and activation of platelets and neutrophils with CD47 functionalized blood contacting surfaces. Biomaterials. 33 (24), 5803-5811 (2012).
  16. Stachelek, S. J., et al. The effect of CD47 modified polymer surfaces on inflammatory cell attachment and activation. Biomaterials. 32 (19), 4317-4326 (2011).
  17. Inamdar, V. V., et al. Stability and bioactivity of pepCD47 attachment on stainless steel surfaces. Acta Biomaterialia. 104, 231-240 (2020).
  18. Fishbein, I., et al. Local delivery of gene vectors from bare-metal stents by use of a biodegradable synthetic complex inhibits in-stent restenosis in rat carotid arteries. Circulation. 117 (16), 2096-2103 (2008).
  19. Moser, K. V., Humpel, C. Primary rat monocytes migrate through a BCEC-monolayer and express microglia-markers at the basolateral side. Brain Research Bulletin. 74 (5), 336-343 (2007).
  20. vander Giessen, W. J., et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation. 94 (7), 1690-1697 (1996).
  21. Fishbein, I., et al. Bisphosphonate-mediated gene vector delivery from the metal surfaces of stents. Proceedings of the National Academy of Sciences of the United States of America. 103 (1), 159-164 (2006).
  22. Mouro-Chanteloup, I., et al. Evidence that the red cell skeleton protein 4.2 interacts with the Rh membrane complex member CD47. Blood. 101 (1), 338-344 (2003).
  23. Finley, M. J., Clark, K. A., Alferiev, I. S., Levy, R. J., Stachelek, S. J. Intracellular signaling mechanisms associated with CD47 modified surfaces. Biomaterials. 34 (34), 8640-8649 (2013).
  24. Slee, J. B., Alferiev, I. S., Levy, R. J., Stachelek, S. J. The use of the ex vivo Chandler Loop Apparatus to assess the biocompatibility of modified polymeric blood conduits. Journal of Visualized Experiments. (90), e51871(2014).

Access restricted. Please log in or start a trial to view this content.

Reprints and Permissions

Request permission to reuse the text or figures of this JoVE article

Request Permission

Tags

CD47 Peptide ImmobilizationMetal Surface ModificationPeptide Conjugation ProtocolPABT PEI PDT FunctionalizationFluorescence Microscopy AnalysisFlow Cytometry CompatibilityStent Biocompatibility ImprovementTherapeutic Peptide AttachmentMetallic Biomaterial Coating

Related Articles